SCYNEXIS (SCYX) Stock Overview
A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SCYX Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
SCYNEXIS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.59 |
| 52 Week High | US$1.49 |
| 52 Week Low | US$0.56 |
| Beta | 1.36 |
| 1 Month Change | -14.93% |
| 3 Month Change | -44.09% |
| 1 Year Change | -41.24% |
| 3 Year Change | -62.37% |
| 5 Year Change | -92.33% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?
Sep 09
Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely
May 17Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop
Jun 19SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 12SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Shareholder Returns
| SCYX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.4% | 1.3% | 1.3% |
| 1Y | -41.2% | 26.0% | 15.8% |
Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 26% over the past year.
Return vs Market: SCYX underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| SCYX volatility | |
|---|---|
| SCYX Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SCYX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SCYX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 28 | David Angulo | www.scynexis.com |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
SCYNEXIS, Inc. Fundamentals Summary
| SCYX fundamental statistics | |
|---|---|
| Market cap | US$24.64m |
| Earnings (TTM) | -US$25.30m |
| Revenue (TTM) | US$2.93m |
Is SCYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCYX income statement (TTM) | |
|---|---|
| Revenue | US$2.93m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.93m |
| Other Expenses | US$28.23m |
| Earnings | -US$25.30m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 100.00% |
| Net Profit Margin | -862.89% |
| Debt/Equity Ratio | 0% |
How did SCYX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 02:08 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCYNEXIS, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Corey Davis | Canaccord Genuity |
| Liisa Bayko | Citizens JMP Securities, LLC |